Medical/Pharmaceuticals
Innovent Announces First Patient Dosed in Phase I Clinical Trial of Anti-PD-1/HER2 Bispecific Antibody in China
SUZHOU, China, Nov. 27, 2019 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent" or "the Company") (HKEX: 01801), a world-class biopharmaceutical company that develops and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic and other major diseases, today ...
2019-11-27 07:50
3601
Global Cord Blood Corporation Reports Financial Results for the Second Quarter and First Half of Fiscal 2020
HONG KONG, Nov. 27, 2019 /PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO) ("GCBC" or the "Company"),China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today announced its unaudited financial results for...
2019-11-27 05:16
11270
New Study by TauRx Shows a Minimum Dose of Hydromethylthionine Could Slow Cognitive Decline and Brain Atrophy in Mild-to-moderate Alzheimer's Disease
ABERDEEN, Scotland and SINGAPORE, Nov. 27, 2019 /PRNewswire/ -- In a paper published in today's online issue of theJournal of Alzheimer's Disease (DOI 10.3233/JAD-190772), TauRx has reported unexpected results of a pharmacokinetic analysis of the relationship between treatment dose, blood levels ...
2019-11-27 02:31
1706
Philips Commended by Frost & Sullivan for Advancing Access to Affordable, High-quality Care through Its Incisive CT Platform
The platform empowers healthcare providers and organizations to deliver on the value-based care promise LONDON, Nov. 26, 2019 /PRNewswire/ -- Based on its recent analysis of the global computed tomography (CT) market, Frost & Sullivan recognizesRoyal Philips (Philips) with the 2019 Global Custom...
2019-11-26 22:00
1203
Japan and Singapore Grant CRISPR Patents to Merck
- Merck now holds 22 CRISPR-related patents worldwide across nine different geographies - Patents cover Paired Cas9 Nickase CRISPR genome-editing technology to advance gene therapy and research DARMSTADT, Germany, Nov. 26, 2019 /PRNewswire/ -- Merck, a leading science and technology company, to...
2019-11-26 21:00
2159
Novoheart to Co-develop First of its Kind Human Heart-in-a-Jar Model of Heart Failure with AstraZeneca
* Heart failure is a global pandemic with an estimated 64.3 million cases worldwide in 2017, costing overUS$100B per year * Drug developers currently lack effective humanized models for preclinical testing of targeted drug candidates in heart failure with preserved ejection fraction * The c...
2019-11-26 16:31
2486
Blockchain in Healthcare Will Live Up to the Hype Versus Reality for Stakeholders
SANTA CLARA, California, Nov. 25, 2019 /PRNewswire/ -- With the healthcare industry increasingly going digital, blockchain technology provides the much-needed trust, security, and auditability for healthcare data on its intelligence journey, which allows blockchain to complement healthcare artifi...
2019-11-25 22:10
1559
Xinhua Silk Road: Er-Kang highly recognized for "going global" achievements in Cambodia
PHNOM PENH, Cambodia, Nov. 25, 2019 /PRNewswire/ -- Hunan Er-Kang (Cambodia) Investment Co., Ltd., an overseas arm ofChina's Hunan Er-Kang Pharmaceutical Co., Ltd. (300267.SZ), has recently received a delegation of Communist Party led by Du Jiahao, Secretary of the CPC Hunan Provincial Committee,...
2019-11-25 18:16
1660
ActLight: Ultra Small, Very Low Power Consumption Heart Rate Monitoring Sensor for Hearables? You Need the ActLight Dynamic Photodiode
LAUSANNE, Switzerland, Nov. 25, 2019 /PRNewswire/ -- Long battery life,
precision of measurements and very small size are the key requirements for
vital signs monitoring sensors in hearable devices.
2019-11-25 08:19
2188
Pfizer Unveils Positive Results from Asian Subgroup Analysis of ARCHER 1050
SINGAPORE, Nov. 25, 2019 /PRNewswire/ -- Pfizer Inc. (NYSE: PFE) today announced the efficacy and tolerability results from the subgroup analysis of Asian patients enrolled in the ARCHER 1050, a randomized, multicenter, multinational, open-label Phase 3 study evaluating the efficacy of VIZIMPRO® ...
2019-11-25 08:15
2176
Positive Interim Efficacy Data from GDC-0084 Phase II Study in Glioblastoma Released at SNO Conference
SYDNEY, Nov. 25, 2019 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to share with investors interim data from its ongoing phase II study of GDC-0084 in glioblastoma, the most common and most aggressive form of...
2019-11-25 07:00
2133
WuXi Vaccines to Build a $240 Million Manufacturing Facility in Ireland
DUNDALK, Ireland, Nov. 23, 2019 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development, and manufacturing, announced that its subsidiary WuXi Vaccines, engaged in ...
2019-11-23 01:55
5570
Patient Enrollment Completed in Phase III Clinical Study of Adapalene-Clindamycin Combination Gel in China
BEIJING, Nov. 22, 2019 /PRNewswire/ -- China Ophthalmology Focus Limited ("COPFL") today announced that its wholly-owned subsidiary, Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Limited ("ZKO") has successfully completed patient enrollment of the Phase III study of Adapalene-Clindamycin Combin...
2019-11-22 23:50
3482
Guardant Health AMEA wins this year's Growth Excellence Leadership Award by Frost & Sullivan
SINGAPORE, Nov. 22, 2019 /PRNewswire/ -- Guardant Health AMEA has won Frost & Sullivan's Growth Excellence Leadership Award under the Best Practices Category for 2019 Asia-Pacific Liquid Biopsy for Precision Oncology. "We are delighted to receive this prestigious award from Frost & Sullivan. T...
2019-11-22 15:37
1689
Thrombosis Research Institute (TRI) Launches Innovative Risk Calculator for Predicting Stroke, Major Bleeding and Mortality in Atrial Fibrillation Over Two Years
- Rapidly predicts differences in risk when treated with different anticoagulants or not treated - Crucially, risk is calculated using patient-specific measurements rather than standardised measures, providing personalised results - Underscored by data of 52,000 AF patients and externally vali...
2019-11-21 23:05
2809
Global Cord Blood Corporation to Report Second Quarter and First Half Fiscal 2020 Financial Results
HONG KONG, Nov. 21, 2019 /PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO) (the "Company"),China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today announced that it plans to release unaudited financia...
2019-11-21 20:00
5944
Week's Top Stories
Most Reposted
Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 305 media titles]
2024-11-20 13:29Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 299 media titles]
2024-11-20 16:30
Travel loyalty programs to focus on offering personalized and flexible customer experiences in 2025
[Picked up by 298 media titles]
2024-11-19 10:42Oxygen, HubSpot's leading solutions partner in Hong Kong & Greater China Expands to UAE
[Picked up by 296 media titles]
2024-11-15 15:25
Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
[Picked up by 283 media titles]
2024-11-20 09:00
Most Read
Oxygen, HubSpot's leading solutions partner in Hong Kong & Greater China Expands to UAE
2024-11-15 15:25
8676
How "small apples" march into "big industry" in Yan'an
2024-11-15 17:39
5434
Strategic Forum in Chongqing Drives Expansion of New Western Land-Sea Corridor
2024-11-16 14:15
4839